Pharma Firms Will ‘Walk Away’ From Gene Therapies Unless Payers Share Risk

 
• By Eliza Slawther
  
Pharmaceutical companies will turn their backs on gene therapies if national agencies do not share risks

More from Pink Sheet

More from Rare Diseases